Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Robert Martell, M.D., Ph.D., to its Board of Directors. Dr. Martell is currently the Director of the Neely Center for Clinical Cancer Research and the Leader of the Program in Experimental Therapeutics at the Tufts Medical Center Cancer Center as well as an Associate Professor of Medicine at the Tufts University School of Medicine. Curis also announced the retirement of Joseph M. Davie, M.D., Ph.D. from its board of directors. “We are delighted to welcome Dr. Martell to Curis. We believe that with his depth of experience in oncology patient care as well as his industry experience in large pharmaceutical and smaller biotechnology companies, he will bring important insights and perspectives to our board and management team on an immediate and long-term basis,” said Curis President and Chief Executive Officer Dan Passeri. “In addition, we would like to thank Dr. Davie for his several years of service on the Curis board. He provided us with scientific guidance during his time with Curis, including serving as chairman of our scientific advisory board for a number of years and we wish him well in his retirement.” Since September 2009, Dr. Martell has been employed by the Tufts Medical Center, serving as both the Director of the Neely Center for Clinical Cancer Research, overseeing oncology clinical research, and the Leader of the Cancer Center’s Program in Experimental Therapeutics, where he is responsible for developing the center’s Phase I oncology clinical development program. Dr. Martell is also an Associate Professor of Medicine at the Tufts University School of Medicine. Previously, Dr. Martell served as Vice President and Chief Medical Officer of MethylGene, a publicy-traded biotechnology company focused on the development of cancer therapeutics, including those targeting HDAC. Dr. Martell also served as Director of Oncology Global Clinical Research at Bristol-Myers Squibb Company, where he worked with molecular-targeted drugs in areas such as multi-target kinase inhibitors (including the panHER inhibitor program), CDK2 inhibitor and was closely involved in the Biologic Licensing Application (BLA) for Erbitux, an antibody that targets EGFR.